Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Cenegermin to Enhance Corneal Nerve Regeneration After SMILE
ChiCTR2100044759Phase 4Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of cenegermin in ocular surface disease (OSD) and neuropathic corneal pain (NCP) (2 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Tear break-up time. Started Feb 2021; status: recruiting.
02
Drugs
cenegermin
03
Conditions
ocular surface disease (OSD)neuropathic corneal pain (NCP)
Beyond the preview
Go deeper on ChiCTR2100044759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044759.